It's about time. A month of rampant speculation fueled by a flurry of media reports citing unnamed sources finally culminated in Genzyme Corp.'s publicly acknowledged receipt of a $69-per-share buyout bid from Sanofi-Aventis SA, and the big biotech wasted no time rejecting the roughly $18.5 billion offer as too low. (BioWorld Today) Read More